Ascites in cirrhosis: A review of management and complications

Netherlands Journal of Medicine

Volumn 65, Issue 8, 2007, Pages 283-288

  Kuiper, J J ^a   van Buuren, H R ^a   de Man, R A ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

Ascites; Cirrhosis; Diagnosis; Treatment

Indexed keywords

ALBUMIN; AMILORIDE PLUS HYDROCHLOROTHIAZIDE; AMOXICILLIN PLUS CLAVULANIC ACID; CEFOTAXIME; CEPHALOSPORIN; DEXTRAN; DIURETIC AGENT; FUROSEMIDE; LACTULOSE; LOOP DIURETIC AGENT; MIDODRINE; NITRIC OXIDE; NORADRENALIN; NORFLOXACIN; OCTREOTIDE; PLASMA SUBSTITUTE; POLYGELINE; SODIUM CHLORIDE; SPIRONOLACTONE; TERLIPRESSIN; VASOCONSTRICTOR AGENT; VASOPRESSIN DERIVATIVE;

ABDOMINAL RADIOGRAPHY; ADRENERGIC SYSTEM; ASCITES; BACTERIAL INFECTION; BACTERIAL PERITONITIS; BOLUS INJECTION; BRAIN DISEASE; DISEASE SEVERITY; DRUG DOSE INCREASE; DRUG MECHANISM; GYNECOMASTIA; HEART OUTPUT; HEPATIC ENCEPHALOPATHY; HEPATORENAL SYNDROME; HUMAN; HYPERKALEMIA; HYPONATREMIA; ISCHEMIA; KIDNEY FAILURE; LIVER CIRRHOSIS; LIVER FAILURE; LIVER TRANSPLANTATION; LONG TERM CARE; LOW DRUG DOSE; MORTALITY; MULTIPLE ORGAN FAILURE; OPTIMAL DRUG DOSE; PARACENTESIS; PATHOPHYSIOLOGY; PHYSICAL EXAMINATION; PLASMA VOLUME; PORTAL VEIN BLOOD PRESSURE; PORTOSYSTEMIC ANASTOMOSIS; POSTOPERATIVE CARE; PROGNOSIS; RECOMMENDED DRUG DOSE; RECURRENCE RISK; RECURRENT DISEASE; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; SEPTIC SHOCK; SHORT COURSE THERAPY; SODIUM EXCRETION; SODIUM RESTRICTION; SODIUM RETENTION; STENT; TREATMENT INDICATION; URINALYSIS; WATER RETENTION;

ANTIBIOTIC PROPHYLAXIS; ASCITES; HUMANS; LIVER CIRRHOSIS; PARACENTESIS; PERITONITIS; RISK FACTORS;

EID: 34948911429     PISSN: 03002977     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (53)

1. Gines P, Quintero E, Arroyo V, et al. Compensated cirrhosis: natural history and prognostic factors. Hepatology 1987;7(1):122-8.
2. Runyon BA, Montana AA, Akriviadis EA, Antillon MR, Irving MA, McHutchison JG. The serum-ascites albumin gradient is superior to the exudate-transudate concept in the differential diagnosis of ascites. Ann Intern Med 1992;117(3):215-20.
3. Fattovich G, Giustina G, Degos F, et al. Morbidity and mortality in compensated cirrhosis type C: a retrospective follow-up study of 384 patients. Gastroenterology 1997;112(2):463-72.
4. Gines P, Arroyo V, Rodes J, Schrier RW. Ascites and renal dysfunction in liver disease. 2nd ed. Malden, MA: Blackwell Publishing Ltd, 2005.
5. Saadeh S, Davis GL. Management of ascites in patients with end-stage liver disease. Rev Gastroenterol Disord 2004;4(4):175-85.
6. D'Amico G, Morabito A, Pagliaro L, Marubini E. Survival and prognostic indicators in compensated and decompensated cirrhosis. Dig Dis Sci 1986;31(5):468-75.
7. Arroyo V, Jimenez W. Complications of cirrhosis. II. Renal and circulatory dysfunction. Lights and shadows in an important clinical problem. J Hepatol 2000;32(1 Suppl):157-70.
8. Gentilini P, Vizzutti F, Gentilini A, Zipoli M, Foschi M, Romanelli RG. Update on ascites and hepatorenal syndrome. Dig Liver Dis 2002;34(8):592-605.
9. Heneghan MA, Harrison PM. Pathogenesis of ascites in cirrhosis and portal hypertension. Med Sci Monit 2000;6(4):807-16.
10. Kuiper JJ, de Man RA, van Buuren HR. Hepatic hydrothorax. Ned Tijdschr Geneeskd 2006;150(21):1157-61.
11. Gines P, Cardenas A, Arroyo V, Rodes J. Management of cirrhosis and ascites. N Engl J Med 2004;350(16):1646-54.
12. Runyan BA. Management of adult patients with ascites due to cirrhosis. Hepatology 2004;39(3):841-56.
13. Santos J, Planas R, Pardo A, et al. Spironolactone alone or in combination with furosemide in the treatment of moderate ascites in nonazotemic cirrhosis. A randomized comparative study of efficacy and safety. J Hepatol 2003;39(2):187-92.
14. Moore KP, Wang F, Gines P, et al. The management of ascites in cirrhosis: report on the consensus conference of the International Ascites Club. Hepatology 2003;38(1):258-66.
15. Schrier RW, Gross P, Gheorghiade M, et al. Tolvaptan, a selective oral vasopressin V2-receptor antagonist, for hyponatremia. N Engl J Med 2006;355(20):2099-112.
16. Thuluvath PJ, Maheshwari A, Wong F, et al. Oral V2 receptor antagonist (RWJ-351647) in patients with cirrhosis and ascites: a randomized, double-blind, placebo-controlled, single ascending dose study. Aliment Pharmacol Ther 2006;24(6):973-82.
17. Yeates KE, Morton AR. Vasopressin antagonists: role in the management of hyponatremia. Am J Nephrol 2006;26(4):348-55.
18. Arroyo V, Gines P, Gerbes AL, et al. Definition and diagnostic criteria of refractory ascites and hepatorenal syndrome in cirrhosis. International Ascites Club. Hepatology 1996;23(1):164-76.
19. Ruiz-del-Arbol L, Monescillo A, Jimenez W, Garcia-Plaza A, Arroyo V, Rodes J. Paracentesis-induced circulatory dysfunction: mechanism and effect on hepatic hemodynamics in cirrhosis. Gastroenterology 1997;113(2):579-86.
20. Coll S, Vila MC, Molina L, Gimenez MD, Guarner C, Sola R. Mechanisms of early decrease in systemic vascular resistance after total paracentesis: influence of flow rate of ascites extraction. Eur J Gastroenterol Hepatol 2004;16(3):347-53.
21. Vila MC, Sola R, Molina L, et al. Hemodynamic changes in patients developing effective hypovolemia after total paracentesis. J Hepatol 1998;28(4):639-45.
22. Garcia-Compean D, Blanc P, Larrey D, et al. Treatment of cirrhotic tense ascites with Dextran-40 versus albumin associated with large volume paracentesis: a randomized controlled trial. Ann Hepatol 2002;1(1):29-35.
23. Gines A, Fernandez-Esparrach G, Monescillo A, et al. Randomized trial comparing albumin, dextran 70, and polygeline in cirrhotic patients with ascites treated by paracentesis. Gastroenterology 1996;111(4):1002-10.
24. Sola-Vera J, Minana J, Ricart E, et al. Randomized trial comparing albumin and saline in the prevention of paracentesis-induced circulatory dysfunction in cirrhotic patients with ascites. Hepatology 2003;37(5):1147-53.
25. Moreau R, Valla DC, Durand-Zaleski I, et al. Comparison of outcome in patients with cirrhosis and ascites following treatment with albumin or a synthetic colloid: a randomised controlled pilot trial. Liver Int 2006;26(1):46-54.
26. Moreau R, Asselah T, Condat B, et al. Comparison of the effect of terlipressin and albumin on arterial blood volume in patients with cirrhosis and tense ascites treated by paracentesis: a randomised pilot study. Gut 2002;50(1):90-4.
27. Moreau R, Lebrec D. The use of vasoconstrictors in patients with cirrhosis: type 1 HRS and beyond. Hepatology 2006;43(3):385-94.
28. Singh V, Kumar B, Nain CK, et al. Noradrenaline and albumin in paracentesis-induced circulatory dysfunction in cirrhosis: a randomized pilot study. J Intern Med 2006;260(1):62-8.
29. Singh V, Kumar R, Nain CK, Singh B, Sharma AK. Terlipressin versus albumin in paracentesis-induced circulatory dysfunction in cirrhosis: a randomized study. J Gastroenterol Hepatol 2006;21(1 Pt 2):303-7.
30. Abraldes JG, Tarantino I, Turnes J, Garcia-Pagan JC, Rodes J, Bosch J. Hemodynamic response to pharmacological treatment of portal hypertension and long-term prognosis of cirrhosis. Hepatology 2003;37(4):902-8.
31. Quiroga J, Sangro B, Nunez M, et al. Transjugular intrahepatic portal-systemic shunt in the treatment of refractory ascites: effect on clinical, renal, humoral, and hemodynamic parameters. Hepatology 1995;21(4):986-94.
32. Wong W, Liu P, Blendis L, Wong F. Long-term renal sodium handling in patients with cirrhosis treated with transjugular intrahepatic portosystemic shunts for refractory ascites. Am J Med 1999;106(3):315-22.
33. Garcia-Tsao G. The transjugular intrahepatic portosystemic shunt for the management of cirrhotic refractory ascites. Nat Clin Pract Gastroenterol Hepatol 2006;3(7):380-9.
34. Russo MW, Sood A, Jacobson IM, Brown RS Jr. Transjugular intrahepatic portosystemic shunt for refractory ascites: an analysis of the literature on efficacy, morbidity, and mortality. Am J Gastroenterol 2003;98(11):2521-7.
35. ter Borg PC, Hollemans M, van Buuren HR, et al. Transjugular intrahepatic portosystemic shunts: long-term patency and clinical results in a patient cohort observed for 3-9 years. Radiology 2004;231(2):537-45.
36. Kochar N, Tripathi D, Ireland H, Redhead DN, Hayes PC. Transjugular intrahepatic portosystemic stent shunt (TIPSS) modification in the management of post-TIPSS refractory hepatic encephalopathy. Gut 2006;55(11):1617-23.
37. Tripathi D, Ferguson J, Barkell H, et al. Improved clinical outcome with transjugular intrahepatic portosystemic stent-shunt utilizing polytetrafluoroethylene-covered stents. Eur J Gastroenterol Hepatol 2006;18(3):225-32.
38. Tripathi D, Redhead D. Transjugular intrahepatic portosystemic stent-shunt: technical factors and new developments. Eur J Gastroenterol Hepatol 2006;18(11):1127-33.
39. Gines P, Arroyo V, Vargas V, et al. Paracentesis with intravenous infusion of albumin as compared with peritoneovenous shunting in cirrhosis with refractory ascites. N Engl J Med 1991;325(12):829-35.
40. Rimola A, Garcia-Tsao G, Navasa M, et al. Diagnosis, treatment and prophylaxis of spontaneous bacterial peritonitis: a consensus document. International Ascites Club. J Hepatol 2000;32(1):142-53.
41. Guarner C, Soriano G. Bacterial translocation and its consequences in patients with cirrhosis. Eur J Gastroenterol Hepatol 2005;17(1):27-31.
42. Kalaitzakis E, Johansson JE, Bjarnason I, Bjornsson E. Intestinal permeability in cirrhotic patients with and without ascites. Scand J Gastroenterol 2006;41(3):326-30.
43. Fernandez J, Navasa M, Gomez J, et al. Bacterial infections in cirrhosis: epidemiological changes with invasive procedures and norfloxacin prophylaxis. Hepatology 2002;35(1):140-8.
44. Singh N, Wagener MM, Gayowski T. Changing epidemiology and predictors of mortality in patients with spontaneous bacterial peritonitis at a liver transplant unit. Clin Microbiol Infect 2003;9(6):531-7.
45. Portal hypertension IV: proceedings from the fourth Baveno International Consensus Workshop. Blackwell Publishing ltd; 2006.
46. Runyon BA, McHutchison JG, Antillon MR, Akriviadis EA, Montano AA. Short-course versus long-course antibiotic treatment of spontaneous bacterial peritonitis. A randomized controlled study of 100 patients. Gastroenterology 1991;100(6):1737-42.
47. Rimola A, Salmeron JM, Clemente G, et al. Two different dosages of cefotaxime in the treatment of spontaneous bacterial peritonitis in cirrhosis: results of a prospective, randomized, multicenter study. Hepatology 1995;21(3):674-9.
48. Ricart E, Soriano G, Novella MT, et al. Amoxicillin-clavulanic acid versus cefotaxime in the therapy of bacterial infections in cirrhotic patients. J Hepatol 2000;32(4):596-602.
49. Fernandez J, Monteagudo J, Bargallo X, et al. A randomized unblinded pilot study comparing albumin versus hydroxyethyl starch in spontaneous bacterial peritonitis. Hepatology 2005;42(3):627-34.
50. Sort P, Navasa M, Arroyo V, Aldeguer X, et al. Effect of intravenous albumin on renal impairment and mortality in patients with cirrhosis and spontaneous bacterial peritonitis. N Engl J Med 1999;341(6):403-9.
51. Kuiper JJ BvH, Man de RA Limited role for routine ascitic culture as a diagnostic tool for spontaneous bacterial peritonitis in the era of prophylactic antibiotics. J Hepatol 2007;46(suppl 1):S96.
52. Ruiz-del-Arbol L, Monescillo A, Arocena C, et al. Circulatory function and hepatorenal syndrome in cirrhosis. Hepatology 2005;42(2):439-47.
53. Salerno F, Gerbes A, Gines P, Wong F, Arroyo V. Diagnosis, prevention and treatment of the hepatorenal syndrome in cirrhosis. A consensus workshop of the international ascites club. Gut 2007; epub ahead of print.